<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Immunology</journal-id>
<journal-id journal-id-type="iso-abbrev">Immunology</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1365-2567</journal-id>
<journal-id journal-id-type="publisher-id">IMM</journal-id>
<journal-title-group>
<journal-title>Immunology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0019-2805</issn>
<issn pub-type="epub">1365-2567</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28704576</article-id>
<article-id pub-id-type="pmc">5629440</article-id>
<article-id pub-id-type="doi">10.1111/imm.12795</article-id>
<article-id pub-id-type="publisher-id">IMM12795</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Psychosis: an autoimmune disease?</article-title>
<alt-title alt-title-type="left-running-head">A. A. J. Al‐Diwani <italic>et al</italic>.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="imm12795-cr-0001">
<name>
<surname>Al‐Diwani</surname>
<given-names>Adam A. J.</given-names>
</name>
<xref ref-type="aff" rid="imm12795-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="imm12795-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="imm12795-note-0001">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="imm12795-cr-0002">
<name>
<surname>Pollak</surname>
<given-names>Thomas A.</given-names>
</name>
<xref ref-type="aff" rid="imm12795-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="imm12795-note-0001">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="imm12795-cr-0003">
<name>
<surname>Irani</surname>
<given-names>Sarosh R.</given-names>
</name>
<xref ref-type="aff" rid="imm12795-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="imm12795-cr-0004">
<name>
<surname>Lennox</surname>
<given-names>Belinda R.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4972-8786</contrib-id>
<address>
<email>belinda.lennox@psych.ox.ac.uk</email>
</address>
<xref ref-type="aff" rid="imm12795-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="imm12795-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>Warneford Hospital</institution>
<institution>University of Oxford</institution>
<named-content content-type="city">Oxford</named-content>
<country country="GB">UK</country>
</aff>
<aff id="imm12795-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Autoimmune Neurology Group</named-content>
<named-content content-type="organisation-division">Nuffield Department of Clinical Neurosciences</named-content>
<institution>John Radcliffe Hospital</institution>
<institution>University of Oxford</institution>
<named-content content-type="city">Oxford</named-content>
<country country="GB">UK</country>
</aff>
<aff id="imm12795-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Psychosis Studies</named-content>
<institution>Institute of Psychiatry, Psychology and Neuroscience</institution>
<institution>King's Health Partners</institution>
<named-content content-type="city">London</named-content>
<country country="GB">UK</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>
Correspondence: Belinda R. Lennox, Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK. Email: <email>belinda.lennox@psych.ox.ac.uk</email><break></break>
Senior author: Belinda R. Lennox<break></break></corresp>
<fn fn-type="equal" id="imm12795-note-0001">
<label>†</label>
<p>These authors contributed equally.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>11</month>
<year>2017</year>
</pub-date>
<volume>152</volume>
<issue>3</issue>
<issue-id pub-id-type="doi">10.1111/imm.2017.152.issue-3</issue-id>
<fpage>388</fpage>
<lpage>401</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>03</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2017 John Wiley &amp; Sons Ltd</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:IMM-152-388.pdf" xlink:type="simple"></self-uri>
<abstract id="imm12795-abs-0001">
<title>Summary</title>
<p>Psychotic disorders are common and disabling. Overlaps in clinical course in addition to epidemiological and genetic associations raise the possibility that autoimmune mechanisms may underlie some psychoses, potentially offering novel therapeutic approaches. Several immune loci including the major histocompatibility complex and B‐cell markers <styled-content style="fixed-case">CD</styled-content>19 and <styled-content style="fixed-case">CD</styled-content>20 achieve genome‐wide significance in schizophrenia. Emerging evidence suggests a potential role via neurodevelopment in addition to classical immune pathways. Additionally, lymphocyte biology is increasingly investigated. Some reports note raised peripheral <styled-content style="fixed-case">CD</styled-content>19<sup>+</sup> and reduced <styled-content style="fixed-case">CD</styled-content>3<sup>+</sup> lymphocyte counts, with altered <styled-content style="fixed-case">CD</styled-content>4 : CD8 ratios in acute psychosis. Also, post‐mortem studies have found <styled-content style="fixed-case">CD</styled-content>3<sup>+</sup> and <styled-content style="fixed-case">CD</styled-content>20<sup>+</sup> lymphocyte infiltration in brain regions that are of functional relevance to psychosis. More specifically, the recent paradigm of neuronal surface antibody‐mediated (<styled-content style="fixed-case">NSA</styled-content>b) central nervous system disease provides an antigen‐specific model linking adaptive autoimmunity to psychopathology. <styled-content style="fixed-case">NSA</styled-content>bs bind extracellular epitopes of signalling molecules that are classically implicated in psychosis such as <styled-content style="fixed-case">NMDA</styled-content> and <styled-content style="fixed-case">GABA</styled-content> receptors. This interaction may cause circuit dysfunction leading to psychosis among other neurological features in patients with autoimmune encephalitis. The detection of these cases is crucial as autoimmune encephalitis is ameliorated by commonly available immunotherapies. Meanwhile, the prevalence and relevance of these antibodies in people with isolated psychotic disorders is an area of emerging scientific and clinical interest. Collaborative efforts to achieve larger sample sizes, comparison of assay platforms, and placebo‐controlled randomized clinical trials are now needed to establish an autoimmune contribution to psychosis.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="imm12795-kwd-0001">autoimmunity</kwd>
<kwd id="imm12795-kwd-0002">neuronal surface antibody</kwd>
<kwd id="imm12795-kwd-0003">psychosis</kwd>
<kwd id="imm12795-kwd-0004">schizophrenia</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Wellcome Trust</funding-source>
<award-id>205126/Z/16/Z</award-id>
<award-id>105758/Z/14/Z</award-id>
</award-group>
<award-group>
<funding-source>Oxford NIHR Biomedical Research Centre</funding-source>
</award-group>
<award-group>
<funding-source>UCB‐Oxford Alliance</funding-source>
</award-group>
<award-group>
<funding-source>Epilepsy Research UK</funding-source>
</award-group>
<award-group>
<funding-source>MedImmune</funding-source>
</award-group>
<award-group>
<funding-source>British Medical Association–Vera Down Grant</funding-source>
</award-group>
<award-group>
<funding-source>NIHR CLAHRC Oxford</funding-source>
</award-group>
<award-group>
<funding-source>Biotest</funding-source>
</award-group>
<award-group>
<funding-source>Lundbeck Foundation</funding-source>
</award-group>
<award-group>
<funding-source>MRC and Stanley Medical Research Centre</funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="1"></table-count>
<page-count count="14"></page-count>
<word-count count="10761"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>imm12795</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>November 2017</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.1 mode:remove_FC converted:06.10.2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>